Replay Conf call - Janssen deal & Replay Webcast - ITP Ph2 & AML Ph1/2 data

2014

arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire

December 11, 2014

  • Shire to take one or more collaborative product candidates into preclinical development

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that its partner Shire has exercised its option to advance into preclinical development one or more product candidates created out of a 2012 therapeutic antibody alliance between the two companies. As a result of the exercise, arGEN-X will receive a milestone payment from Shire.

arGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model

December 08, 2014

  • Data to be presented at ASH demonstrate potential of ARGX-110 in reversing resistance to tyrosine kinase inhibitors

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces the presentation of preclinical data at the American Society of Hematology (ASH) Annual Meeting highlighting the potential of the CD70 pathway as a targetable mechanism to overcome drug resistance in chronic myelogenous leukemia (CML). The data show that co-treatment of ARGX-110, the Company’s anti-CD70 therapeutic antibody, and imatinib, a first-line BCR/ABL-specific tyrosine kinase inhibitor (TKI), eradicates the disease-initiating CML stem cells, a cell population often resistant to TKI therapy.

arGEN-X – Third Quarter Business Update

November 14, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provides a business update for the third quarter 2014 and financial highlights for the nine months ended 30 September 2014.

arGEN-X Initiates Clinical Efficacy Evaluation of ARGX-110 in Patients with Relapsed/Refractory CD70-Positive T-Cell Lymphomas

November 11, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has initiated a clinical efficacy evaluation of ARGX-110, its investigational anti-CD70 therapeutic antibody, in patients with relapsed/refractory CD70-positive T-cell lymphomas. The evaluation will be conducted as an expansion arm of the ongoing Phase 1b study of ARGX-110.

arGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Waldenström’s Macroglobulinemia

November 03, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b/2 trial of ARGX-110 in patients with relapsed or refractory Waldenström’s macroglobulinemia. ARGX-110 is a novel anti-CD70 antibody currently being evaluated in a Phase 1b study in hematological and solid cancers in Europe.

arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-Positive Hematological Malignancies into its Phase 1b Expansion Trial with ARGX-110

October 15, 2014

  • Based on evidence of activity, T-cell lymphomas selected as indication for initial efficacy studies

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has completed enrolment of the first expansion cohort of 15 patients with CD70-positive hematological malignancies, part of an ongoing open-label Phase 1b trial with ARGX-110, a novel anti-CD70 therapeutic antibody.

arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-positive Solid Tumors into its Phase 1b Expansion Trial with ARGX-110

September 18, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has completed enrolment of a first cohort of 15 patients with CD70-positive solid tumors into an open-label Phase 1b expansion trial with ARGX-110, a novel anti-CD70 therapeutic antibody. Recruitment of a second cohort of 15 patients with CD70-positive hematological malignancies is ongoing. The primary objective of the expansion trial is to select one or more indications to take forward into further clinical trials.

arGEN-X’ Core Patents Protecting Lead Clinical Candidates ARGX-110 and ARGX-111 Receive Accelerated Grant in the United States

September 17, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, is pleased to announce the grant of key patents in the United States relating to its two lead clinical candidates ARGX-110 and ARGX-111.

arGEN-X Appoints Petercam NV as Liquidity Provider to Facilitate Trading on Euronext Brussels

September 15, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today that it has appointed Petercam NV as a liquidity provider for the Company’s common shares currently listed on Euronext Brussels under the trading symbol ARGX.

arGEN-X – Business Update and First Half 2014 Results

August 27, 2014

Breda, the Netherlands / Ghent, Belgium– arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provides a business update and announces its financial results for the first half of 2014 (six-month period ended 30 June 2014).

arGEN-X Announces Positive Preclinical Results for ARGX-113

August 19, 2014

  • Data support ARGX-113 as a potential breakthrough concept for management of flares in severe autoimmune diseases

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the results of a preclinical study assessing the pharmacokinetic and pharmacodynamic (PK/PD) behaviors of ARGX-113, the Company’s most advanced autoimmune product candidate. The data proved ARGX-113 to be highly effective in rapidly clearing a tracer antibody from circulation in a dose-dependent manner in non-human primates, thus acting as a surrogate of autoantibody clearance.

arGEN-X Raises Additional €1.8 million via Exercise of Over-allotment Option and Announces the End of the Stabilization Period

August 11, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (“arGEN-X”, Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces today the partial exercise of the over-allotment option by KBC Securities (the “Stabilization Manager”) acting on behalf of KBC Securities and Kempen & Co (the “Joint Global Coordinators”) and Petercam (the “Co-Lead-Manager”); and the end of the stabilization period, in relation to its Initial Public Offering that ended on 8 July 2014 (the “IPO”).

arGEN-X to Present at the Wedbush 2014 Life Sciences Management Access Conference

August 05, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Wedbush 2014 Life Sciences Management Access Conference in New York City (NY, USA) on Tuesday, 12 August 2014 at 3:05pm EDT.

arGEN-X Raises €40 million in successful Initial Public Offering on Euronext Brussels

July 08, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (“arGEN-X”), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces the successful completion of its Initial Public Offering, which was launched on 23 June 2014 (the “IPO” or the “Offering”). arGEN-X shares will be listed on Euronext Brussels and begin trading on an “if-and-when-issued-or-delivered” basis on Thursday 10 July 2014 under the symbol “ARGX”.

arGEN-X Launches Initial Public Offering on Euronext Brussels

June 20, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the launch of its Initial Public Offering on Euronext Brussels.

arGEN-X Announces Intention to Launch an Initial Public Offering on Euronext Brussels

June 10, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced its intention to raise new funds through an Initial Public Offering on Euronext Brussels.

arGEN-X Enters Long-term Strategic Alliance with Shire Pharmaceuticals in Therapeutic Antibodies

June 04, 2014

  • Significantly expanded relationship created on back of collaboration success

Breda, the Netherlands / Ghent, Belgium – arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals. Under the agreement, arGEN-X will bring its entire suite of human antibody discovery technologies to a partnership focused on multiple targets aligned with Shire’s therapeutic focus. The multi-year initiative aimed at helping augment the Shire development pipeline follows an initial research and development collaboration undertaken in March 2012.

arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO

May 29, 2014

Breda, The Netherlands / Ghent, Belgium – arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced hematological and solid tumors at the 50th annual meeting of the American Society of Clinical Oncology (ASCO; 30 May-3 June, 2014, Chicago, IL, USA).

arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates

May 28, 2014

Breda, the Netherlands – arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X’s SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to addressing complex targets across multiple therapeutic areas that are often intractable by existing antibody platforms.

arGEN-X uses its SIMPLE Antibody™ platform to identify four ‘hotspots’ on MET as targets for its therapeutic antibody program

April 07, 2014

  • New findings to be presented at the American Association for Cancer Research annual meeting

Breda, The Netherlands/Ghent, Belgium – arGEN-X, a clinical stage human therapeutic antibody company, will present data on how its SIMPLE Antibody™ platform has identified four ‘hotspots’ on the MET protein that are suitable for therapeutic antibody targeting. Encoded by the oncogene c-Met, MET signalling is involved in cancer proliferation and metastasis and is activated by hepatocyte growth factor (HGF) in multiple cancers.

arGEN-X Appoints Dr Werner Lanthaler to its Supervisory Board

April 04, 2014

Breda, The Netherlands / Ghent, Belgium – arGEN-X, a clinical stage human therapeutic antibody company, announces that it has appointed Dr. Werner Lanthaler to its Supervisory Board.

arGEN-X receives two preclinical milestone payments under collaboration with Shire

January 13, 2014

  • Enters into pilot research agreement with Boehringer Ingelheim

Breda, the Netherlands / Ghent, Belgium– arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment of two important success milestones in its SIMPLE Antibody™ research and product development collaboration with Shire. The milestones, which trigger undisclosed payments from Shire, relate to demonstration of in vivo proof of concept for one of the ongoing antibody discovery programs.

arGEN-X starts Phase Ib expansion cohorts with ARGX-110, a novel anti-CD70 antibody, in cancer patients

January 07, 2014

  • Study supported by a €3.5 million IWT grant from the Flemish Government

Breda, The Netherlands / Ghent, Belgium – arGEN-X, a clinical stage human therapeutic antibody company, announces that it has advanced ARGX-110, a novel anti-CD70 antibody, into the safety and efficacy expansion part of its Phase Ib study. The objective is to further investigate the safety of ARGX-110 in CD70-positive cancer patients with either haematological or solid tumors, and to evaluate efficacy in order to select the indications to be studied in Phase II clinical development. Top-line results are expected in about 12 months. The study is being supported by a €3.5 million grant from the Flemish Government’s Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).